Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;40(12):1722-1760.
doi: 10.1038/s41587-022-01582-x.

Biopharmaceutical benchmarks 2022

Gary Walsh  1 , Eithne Walsh  2
Affiliations

Biopharmaceutical benchmarks 2022

Gary Walsh et al. Nat Biotechnol. 2022 Dec.

Abstract

Monoclonal antibodies as a group continue to lead biopharmaceuticals in numbers of approvals and sales, although COVID-19 vaccines shot to the top of the list of highest-grossing individual products.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Product approvals profile.
a, Annual product approval numbers (by product trade name) by individual region. b, Number of product approvals in one or both regions over the indicated periods.
Fig. 2
Fig. 2. Monoclonal antibody statistics.
a, mAbs approved for the first time within the indicated periods, expressed as a percentage of total biopharmaceuticals approved for the first time within the same time period. b, Global annual mAb sales value, expressed as a percentage of total protein-based biopharmaceutical global sales for the indicated years. Financial data from LaMerie Business Intelligence.
Fig. 3
Fig. 3. Expression systems.
Relative use of mammalian- versus non-mammalian-based production cell lines in the manufacture of biopharmaceuticals approved over the indicated periods. Each dataset is expressed as a percent of total biopharmaceutical product approvals for the period indicated.
See this image and copyright information in PMC

References

    1. Walsh G. Nat. Biotechnol. 2018;36:1136–1145. doi: 10.1038/nbt.4305. - DOI - PubMed
    1. Walsh G. Nat. Biotechnol. 2014;32:992–1000. doi: 10.1038/nbt.3040. - DOI - PubMed
    1. Walsh G. Nat. Biotechnol. 2010;28:917–924. doi: 10.1038/nbt0910-917. - DOI - PubMed
    1. Walsh G. Nat. Biotechnol. 2006;24:769–776. doi: 10.1038/nbt0706-769. - DOI - PubMed
    1. Kelley, B., Kiss, R. & Laird, M. (2018). in New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins (eds Kiss, B., Gottschalk, U. & Pohlscheidt, M.) 443–462 (Springer, 2018). - PubMed

Substances